Dalteparin detailed information: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 12: | Line 12: | ||
==See also== | ==See also== | ||
*[[Dalteparin Sodium]] | |||
*[[Heparin]] | *[[Heparin]] | ||
==References== | ==References== | ||
Revision as of 16:48, 12 September 2011
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
For patient information, click here
For drug information on Dalteparin, click here
Overview
Dalteparin is a low molecular weight heparin. It is marketed as Fragmin by Eisai. Like other low molecular weight heparins, dalteparin is used for prophylaxis or treatment of deep vein thrombosis and pulmonary embolism.
The CLOT study, published in 2003, showed that in patients with malignancy and acute venous thromboembolism, dalteparin was more effective than coumarin in reducing the risk of recurrent embolic events.[1]